Does long-term dipeptidyl-peptidase 4 inhibition reduce atherosclerosis and inflammation via effects on monocyte recruitment and chemotaxis?
DPP-4i exerts antiatherosclerotic effects and reduces inflammation via inhibition of monocyte activation/chemotaxis. These findings have important implications for the use of this class of drugs in atherosclerosis.
Our findings show that baseline NLR is strongly and independently associated with outcome of patients treated with ipilimumab, and may serve to identify patients most likely to benefit from this therapy.